- Home
- IMCR vs SHO Comparison
IMCR vs SHO Comparison
Compare IMCR & SHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- SHO
- Stock Information
- Founded
- IMCR 2008
- SHO 1995
- Country
- IMCR United Kingdom
- SHO United States
- Employees
- IMCR N/A
- SHO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- SHO Hotels/Resorts
- Sector
- IMCR Health Care
- SHO Consumer Discretionary
- Exchange
- IMCR Nasdaq
- SHO Nasdaq
- Market Cap
- IMCR 1.5B
- SHO 1.7B
- IPO Year
- IMCR 2021
- SHO 1995
- Fundamental
- Price
- IMCR $32.80
- SHO $8.93
- Analyst Decision
- IMCR Buy
- SHO Hold
- Analyst Count
- IMCR 10
- SHO 8
- Target Price
- IMCR $58.13
- SHO $9.56
- AVG Volume (30 Days)
- IMCR 444.9K
- SHO 2.8M
- Earning Date
- IMCR 08-07-2025
- SHO 08-06-2025
- Dividend Yield
- IMCR N/A
- SHO 4.03%
- EPS Growth
- IMCR N/A
- SHO N/A
- EPS
- IMCR N/A
- SHO 0.10
- Revenue
- IMCR $333,581,000.00
- SHO $922,708,000.00
- Revenue This Year
- IMCR $26.82
- SHO $7.67
- Revenue Next Year
- IMCR $8.15
- SHO $3.45
- P/E Ratio
- IMCR N/A
- SHO $91.03
- Revenue Growth
- IMCR 25.75
- SHO N/A
- 52 Week Low
- IMCR $23.15
- SHO $7.45
- 52 Week High
- IMCR $41.54
- SHO $12.41
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- SHO 54.63
- Support Level
- IMCR $30.76
- SHO $8.57
- Resistance Level
- IMCR $33.95
- SHO $9.02
- Average True Range (ATR)
- IMCR 1.39
- SHO 0.25
- MACD
- IMCR -0.15
- SHO 0.02
- Stochastic Oscillator
- IMCR 43.05
- SHO 84.75
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.